Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double Blind, Multicenter, Multinational, Placebo Controlled, Single Parallel Escalating Dose, Safety & Efficacy Study of ACT017 Used as add-on of SoC Therapy in the 4,5 Hrs Post Onset of Acute Ischemic Stroke Symptoms

Trial Profile

Randomized, Double Blind, Multicenter, Multinational, Placebo Controlled, Single Parallel Escalating Dose, Safety & Efficacy Study of ACT017 Used as add-on of SoC Therapy in the 4,5 Hrs Post Onset of Acute Ischemic Stroke Symptoms

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Jan 2019

At a glance

  • Drugs ACT 017 (Primary)
  • Indications Stroke
  • Focus Adverse reactions
  • Acronyms ACTIMIS
  • Sponsors Acticor Biotech
  • Most Recent Events

    • 17 Jan 2019 New source identified and integrated (ClinicalTrials.gov Identifier:NCT03803007)
    • 11 Jan 2019 Status changed from planning to not yet recruiting.
    • 02 May 2018 Location assumed Europe based on European Medicines Agency has cleared the route for a Phase II trial of ACT017 in stroke.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top